KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Share-based Compensation (2018 - 2025)

Moderna (MRNA) has disclosed Share-based Compensation for 8 consecutive years, with $113.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 8.65% to $113.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $483.0 million, a 12.59% increase, with the full-year FY2025 number at $483.0 million, up 12.59% from a year prior.
  • Share-based Compensation was $113.0 million for Q4 2025 at Moderna, down from $125.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $130.0 million in Q2 2025 to a low of $30.0 million in Q1 2021.
  • A 5-year average of $79.2 million and a median of $76.0 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 81.82% in 2021, then grew 8.65% in 2025.
  • Moderna's Share-based Compensation stood at $37.0 million in 2021, then soared by 67.57% to $62.0 million in 2022, then rose by 27.42% to $79.0 million in 2023, then skyrocketed by 31.65% to $104.0 million in 2024, then grew by 8.65% to $113.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Share-based Compensation are $113.0 million (Q4 2025), $125.0 million (Q3 2025), and $130.0 million (Q2 2025).